Publications

Export 15 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Amyloid beta-Peptides  [Clear All Filters]
2020
Gonneaud J, Bedetti C, Binette APichet, Benzinger TLS, Morris JC, Bateman RJ, Poirier J, Breitner JCS, Villeneuve S.  2020.  Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease.. Neurology. 95(11):e1554-e1564.
2019
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
2017
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
2016
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C et al..  2016.  Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.. J Alzheimers Dis. 52(1):51-64.
Chung JKu, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A.  2016.  Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.. J Geriatr Psychiatry Neurol. 29(3):149-59.
Leduc V, Théroux L, Dea D, Dufour R, Poirier J.  2016.  Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.. J Mol Neurosci. 58(1):109-19.
Fletcher E, Villeneuve S, Maillard P, Harvey D, Reed B, Jagust W, DeCarli C.  2016.  β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals.. Neurobiol Aging. 40:173-80.
2015
Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG, Brockschnieder D, Dyrks T, Althoff V, Fraser PE et al..  2015.  Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors.. J Alzheimers Dis. 44(2):613-24.
Breitner JCS.  2015.  Comment: Yet another "disconnect" between amyloid and Alzheimer disease? Neurology. 85(8):698.
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SKate, Vogel JW, Marks SM et al..  2015.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.. Brain. 138(Pt 7):2020-33.
Chung JKu, Plitman E, Nakajima S, Chow TW, Chakravarty MM, Caravaggio F, Gerretsen P, Brown EE, Iwata Y, Mulsant BH et al..  2015.  Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment.. J Alzheimers Dis. 45(3):907-19.
2014
Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner JCS, Dea D.  2014.  Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.. Neurobiol Aging. 35 Suppl 2:S3-10.
Zimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P.  2014.  MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
Leuzy A, Zimmer ERigon, Heurling K, Rosa-Neto P, Gauthier S.  2014.  Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.. Amyloid. 21(3):143-8.